Patient characteristics of the 2 groups
| . | All patients included . | Eligible patients for therapy . |
|---|---|---|
| All patients (n) | 1766 | 1332 |
| Median age (y, range | 60 (15–87) | 59 (15–87) |
| Male/female (n, %) | 916/850 (51.9/48.1) | 681/651 (51.1/48.9) |
| de novo AML (n, %) | 1387 (78.5) | 1045 (78.5) |
| Secondary AML (n, %) | 379 (21.5) | 287 (21.5) |
| History of MDS/RAEB-t (n, %) | 307 | 237 |
| t-AML (n) | 72 | 50 |
| dys 0 + 1 (n, %) | 1244 (70.4) | 923 (69.3) |
| MLD (dys 2+3) (n, %) | 522 (29.6) | 409 (30.7) |
| Cytogenetics (n, %) | 1618 (91.6) | 1253 (94.0) |
| Cytogenetic risk group* (n, %) | ||
| Favorable | 177 (10.0) | 96 (7.2) |
| Intermediate | 1224 (69.3) | 967 (72.6) |
| Unfavorable | 365 (20.7) | 269 (20.2) |
| FLT3-ITD pos/neg (n, %) | —– | 283 (22.9)/954 (77.1) |
| NPM1 mutant/wild type (n, %) | —– | 351 (29.0)/858 (71.0) |
| . | All patients included . | Eligible patients for therapy . |
|---|---|---|
| All patients (n) | 1766 | 1332 |
| Median age (y, range | 60 (15–87) | 59 (15–87) |
| Male/female (n, %) | 916/850 (51.9/48.1) | 681/651 (51.1/48.9) |
| de novo AML (n, %) | 1387 (78.5) | 1045 (78.5) |
| Secondary AML (n, %) | 379 (21.5) | 287 (21.5) |
| History of MDS/RAEB-t (n, %) | 307 | 237 |
| t-AML (n) | 72 | 50 |
| dys 0 + 1 (n, %) | 1244 (70.4) | 923 (69.3) |
| MLD (dys 2+3) (n, %) | 522 (29.6) | 409 (30.7) |
| Cytogenetics (n, %) | 1618 (91.6) | 1253 (94.0) |
| Cytogenetic risk group* (n, %) | ||
| Favorable | 177 (10.0) | 96 (7.2) |
| Intermediate | 1224 (69.3) | 967 (72.6) |
| Unfavorable | 365 (20.7) | 269 (20.2) |
| FLT3-ITD pos/neg (n, %) | —– | 283 (22.9)/954 (77.1) |
| NPM1 mutant/wild type (n, %) | —– | 351 (29.0)/858 (71.0) |
RAEB-t indicates refractory anemia with excess of blasts in transformation; t-AML, therapy-related AML; MLD, multilineage dysplasia as defined by WHO19 ; and —, not applicable.
Cytogenetic risk groups according to CALGB.23